Author Archive | Raynovich Rod

Biotechnology Stock Review 2011:Update 1/2/12

see Here are some key points from our 2011 Biotech Stock Review posted in Investor Uprising: Winners from the 2011 Rayno Life Science Portfolio: Abaxis (ABAX), Alexion(ALXN), Amgen (AMGN), Biogen(BIIB), Bristol-Myers (BMY),Celera(acquired),Cephalon (acquired) Cubist (CBST), Exact Scientific (EXAS),Gilead (GILD), BioETF (IBB), Immucor (acquired), Neogen (NEOG), Regeneron (REGN),Quidel (QDEL), Seattle Genetics (SGEN), United Therapeutics(UTHR) and Viropharma (VPHM) Losers: Alere […]

Continue Reading 0

Rayno Diagnostics and Tools Portfolio: ILMN, NEOG

http://ezeta.com.ar/index.php?option=com_content Life Sciences: Biopharmaceutical Stocks are Hot, Tools and DX are Not We recommended avoiding the Tools/Dx sector several weeks ago as they were lagging biopharmaceutical stocks due to earnings misses, concerns about NIH finding for R&D, and lack of exciting new products. Illumina (ILMN $28.95) is up 6.5% today and has been volatile in the […]

Continue Reading 0

Three Small Cap Stocks for a Rebound in January: AMRI,ASTX,SRLS-UPDATE 1/5/12

go to site January Rally on Schedule for Small Cap Biotech Stocks Three Picks we made on December 14: Albany Molecular (AMRI $2.89) Up 16% Astex Pharmaceuticals (ASTX $1.94) Up 19% SeraCare (SRLS $3.00) Up 1.7% Three healthcare conferences in San Francisco next week Jan. 9-13 should provide news and perhaps another boost for biotech stocks: J.P.Morgan Healthcare […]

Continue Reading 0

Macro News Kills Holiday Buzz: Markets Off 1.6% and More

Rally Hits a Wall at S&P Q4 High of 1265, Down 2%  to 1237 You have heard all the compelling reasons to jump into this market: Seasonality is strong from November through May Charts look good Lots of cash on the sidelines, everyone is underinvested Interest rates are too low for alternative investments- 10 yr. […]

Continue Reading 0

Rayno Life Science Portfolio: Tools Rally- A, LIFE, ILMN, QGEN

medrol 16 mg tabletta Illumina (ILMN $30.23) shares spiked today on takeover speculation. The shares were whacked in July and the stock is down 52% YTD on an earnings miss with no guidance. Revenue estimates from analysts are in the $1B range for 2011 so with the current Market Cap of $3.7B  the Company is not too expensive for […]

Continue Reading 0

Pure Play Diagnostics Roster: Metrics with Q3 Earnings

No new buys, currently on HOLD list: ABAX, EXAS, NEOG, QDEL, SRLS. Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update | Raygent.com Outperformers YTD: ABAX up 2.9%,CPHD up 51%, EXAS up 42%, GHDX up 31%, GPRO up 9%, LMNX up 13%, QDEL up 25%, TECH up 1.5%. Underperformers YTD: ALR down 36%, […]

Continue Reading 0

Macro “Risk On”: Life Science Stock Follow Up 3.4%

Rayno Life Science Portfolios Up 3.4% Two big up days this week were driven primarily by high expectations by Central Bank coordination to cut the cost of emergency dollar funding and news from the People’s Bank of China to cut the reserve ratio.US economic data was also positive with private sector job gains and the […]

Continue Reading 0

Rayno Life Science Portfolios Run With NASDAQ Up 3.79%

Life Science Stocks Have a Big Day  The Rayno Biopharmaceutical Portfolio was up over 3.7% today as all biotechnology stocks pretty much tracked NASDAQ which was up 3.5%. Although we remain cautious with no new buys we have  a good chance for a Q4 rally as the sector is outperforming NASDAQ quarter to date. Within […]

Continue Reading 0

Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks

Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF’s and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89% over Fridays’ close and 519% YTD! Pharmasset has no revenues but has a three potential hepatitis-C treatments in clinical trials that […]

Continue Reading 0

Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars

Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year revenues at  $228M .Also the Center for Medicare and Medicaid Services updated their reimbursement landscape.   Time to Look at Dendreon (DNDN) We have been […]

Continue Reading 0